Cargando…
Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges
PURPOSE: Soft tissue and bone sarcomas are rare malignancies that exhibit significant pathologic and molecular heterogeneity. Deregulation of the CDKN2A-CCND-CDK4/6-retinoblastoma 1 (Rb) pathway is frequently observed in about 25% of unselected sarcomas and is pathognomonic for specific sarcoma subt...
Autores principales: | Hsu, Jocelyn Y., Seligson, Nathan D., Hays, John L., Miles, Wayne O., Chen, James L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820917/ https://www.ncbi.nlm.nih.gov/pubmed/35108033 http://dx.doi.org/10.1200/PO.21.00211 |
Ejemplares similares
-
CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
por: Arsenijevic, Tatjana, et al.
Publicado: (2023) -
CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
por: Schröder, Lisette B. W., et al.
Publicado: (2015) -
Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020) -
Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
por: Martin-Broto, Javier, et al.
Publicado: (2023) -
CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)